Evogene Ltd. (EVGN)
Chart Events
Performance Outlook
| Previous Close | 6.24 |
| Open | 6.17 |
| Bid | 6.13 x 900 |
| Ask | 6.13 x 1100 |
| Day's Range | 5.96 - 6.21 |
| 52 Week Range | 0.75 - 6.94 |
| Volume | 958,942 |
| Avg. Volume | 1,595,883 |
| Market Cap | 228.46M |
| Beta (5Y Monthly) | 0.55 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.82 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 9.00 |
- PR Newswire
Biomica Announces Participation at the Crohn's & Colitis Congress® January 21-24, 2021 (Virtual Conference)
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Crohn's & Colitis Congress® to be held from today January 21-24, 2021.
- PR Newswire
Biomica Announces Participation at the 5th Microbiome Movement Drug Development Europe Conference on January 28-29, 2021 (Virtual Conference)
Biomica Ltd., an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN.TA), today announced it will be featured as a presenting company at the Microbiome Movement Drug Development Europe Conference. The conference is being held on January 28-29, 2021, virtually.
- TheStreet.com
Shark Bites: A Computational Predictive Biology Play
Computation Predictive Biology (CPB) is defined as "the development and application of data-analytical and theoretical methods, mathematical modeling and computational simulation techniques to the study of biological, ecological, behavioral, and social systems." EVGN believes that its CPB platform gives it a competitive edge that increases efficacy, reduces toxicity, cuts costs of development, and saves time. The key areas of development are microbiome therapeutics, herbicides, pesticides, and medical cannabis.
